The Food and Drug Administration (FDA) has approved for adult use many drugs never tested in\ud children. Yet clinicians often prescribe them for children believing that the safety and effectiveness demonstrated with adults probably reasonably transfers to younger patients. The data show that this is not always true. To encourage industry to develop drugs and medical devices for pediatric use, Congress has established three programs. The Food and Drug Administration Amendments Act of 2007 (FDAAA, P.L. 110-85) reauthorized and strengthened two laws addressing drugs—the Best Pharmaceuticals for Children Act (BPCA) of 2002 and the Pediatric Research Equity Act (PREA) of 2003—and enacted a new law addressing devices—the Pediatric Medical Device...
Knowledge of drug administration in children and infants lags behind that of adults for many reasons...
The Food and Drug Administration (“FDA”) has embraced its position as the Gatekeeper of the pharmace...
Purpose A dearth in pediatric drug development often leaves pediatricians with no alternative but to...
Most drugs lack information on their safe and effective use in children. This dilemma limits the num...
Testimony issued by the Government Accountability Office with an abstract that begins "About two-thi...
Children deserve optimal medical care. Although prescription drugs play a prominent and essential ro...
Testimony issued by the General Accounting Office with an abstract that begins "Children fall ill wi...
HISTORICALLY, ONLY 25 % OFapproved drugs marketed inthe United States have suf-ficient pediatric dat...
Children need a distinct medicines-use system designed explicitly for them since their continued inc...
The lack or incompleteness of evidence of the efficacy and safety of drugs used in children has been...
Background: Children are not small adults, but a vulnerable population with developmental, physiolog...
BACKGROUND: Medical devices can be useful in a variety of diseases, but few devices have been specif...
This article discusses the Best Pharmaceuticals for Children Act and the FDA\u27s request for placeb...
For too long children have received medicines not sufficiently studied for their needs and, in fact,...
For most new therapeutic agents, children have been excluded during the drug evaluation process. Com...
Knowledge of drug administration in children and infants lags behind that of adults for many reasons...
The Food and Drug Administration (“FDA”) has embraced its position as the Gatekeeper of the pharmace...
Purpose A dearth in pediatric drug development often leaves pediatricians with no alternative but to...
Most drugs lack information on their safe and effective use in children. This dilemma limits the num...
Testimony issued by the Government Accountability Office with an abstract that begins "About two-thi...
Children deserve optimal medical care. Although prescription drugs play a prominent and essential ro...
Testimony issued by the General Accounting Office with an abstract that begins "Children fall ill wi...
HISTORICALLY, ONLY 25 % OFapproved drugs marketed inthe United States have suf-ficient pediatric dat...
Children need a distinct medicines-use system designed explicitly for them since their continued inc...
The lack or incompleteness of evidence of the efficacy and safety of drugs used in children has been...
Background: Children are not small adults, but a vulnerable population with developmental, physiolog...
BACKGROUND: Medical devices can be useful in a variety of diseases, but few devices have been specif...
This article discusses the Best Pharmaceuticals for Children Act and the FDA\u27s request for placeb...
For too long children have received medicines not sufficiently studied for their needs and, in fact,...
For most new therapeutic agents, children have been excluded during the drug evaluation process. Com...
Knowledge of drug administration in children and infants lags behind that of adults for many reasons...
The Food and Drug Administration (“FDA”) has embraced its position as the Gatekeeper of the pharmace...
Purpose A dearth in pediatric drug development often leaves pediatricians with no alternative but to...